• 1. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 2. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 3. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227
• 4. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 5. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives

Recent Advances in the Application of 5-(Difluoromethyl)pyridine-3-sulfonyl chloride (CAS: 1780034-60-7) in Chemical Biology and Pharmaceutical Research

The compound 5-(Difluoromethyl)pyridine-3-sulfonyl chloride (CAS: 1780034-60-7) has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile reactivity and potential applications in drug discovery. This sulfonyl chloride derivative serves as a key intermediate in the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and other targeted therapies. Recent studies have highlighted its utility in click chemistry reactions and as a building block for proteolysis-targeting chimeras (PROTACs), underscoring its importance in modern medicinal chemistry.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficient use of 5-(Difluoromethyl)pyridine-3-sulfonyl chloride in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized this compound to introduce the difluoromethylpyridine moiety, which significantly improved the pharmacokinetic properties of the resulting inhibitors. The study reported enhanced target engagement and reduced off-target effects compared to previous generation inhibitors, suggesting promising clinical applications for autoimmune diseases and B-cell malignancies.

In the field of chemical biology, recent work published in ACS Chemical Biology has explored the use of 5-(Difluoromethyl)pyridine-3-sulfonyl chloride as a versatile warhead for covalent protein modification. The difluoromethyl group's unique electronic properties, combined with the reactivity of the sulfonyl chloride, enable selective labeling of cysteine residues in complex biological systems. This approach has proven particularly valuable for studying protein-protein interactions and mapping enzyme active sites, providing researchers with powerful tools for target identification and validation.

From a synthetic chemistry perspective, advances in the large-scale production of 5-(Difluoromethyl)pyridine-3-sulfonyl chloride have been reported in Organic Process Research & Development. The new synthetic routes address previous challenges in yield and purity, making this valuable intermediate more accessible for pharmaceutical development. Process optimization has focused on safer handling of the sulfonyl chloride group and more sustainable fluorine incorporation methods, reflecting the industry's growing emphasis on green chemistry principles.

Emerging applications in radiopharmaceuticals have also been documented, with recent patents describing the use of 5-(Difluoromethyl)pyridine-3-sulfonyl chloride as a precursor for PET tracer development. The compound's ability to serve as a labeling handle for fluorine-18 incorporation has opened new possibilities for imaging agent development, particularly in oncology and neuroscience research. These developments highlight the compound's expanding role in both therapeutic and diagnostic applications.

Looking forward, the unique properties of 5-(Difluoromethyl)pyridine-3-sulfonyl chloride position it as a valuable tool in several cutting-edge areas of pharmaceutical research. Its applications in targeted protein degradation, covalent inhibitor design, and imaging probe development continue to evolve, driven by ongoing innovations in synthetic methodology and biological understanding. As research progresses, we anticipate seeing more clinical candidates derived from this versatile building block entering development pipelines across multiple therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)